Transcode Therapeutics Stock News

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics, today reported recent business progress and third quarter 2021 financial results. “TransCode has made further progress across our corporate infrastructure and bourgeoning portfolio, advancing our mission to design RNA therapeutics that can effectively treat cancer. Reflecting the

These penny stocks exploded during today's trading session, are they worth watching or not? The post 5 Penny Stocks to Watch That Exploded Today, What You Need to Know appeared first on Penny Stocks t

The stock price of TransCode Therapeutics, Inc. (Nasdaq: RNAZ) is trading at over 75% during intraday trading today. This is why it happened.

Shares of TransCode Therapeutics Inc (NASDAQ: RNAZ) climbed by 65% on Thursday morning as the oncology company said in its press release that the preclinical research supporting its lead candidate, TT

TransCode Therapeutics Inc (NASDAQ: RNAZ) is trading higher after preclinical research supporting its lead candidate, TTX-MC138, was published in Cancer Nanotechnology.  Related:   TransCode Thera

TransCode Therapeutics Inc (NASDAQ: RNAZ) has received a Fast-Track Small Business Innovation Research (SBIR) grant from the NIH to support developing TTX-MC138. TTX-MC138 is TransCode's lead therape

BOSTON--(BUSINESS WIRE)--TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), an emerging RNA oncology company created on the belief that cancer can be defeated through the inte

After a record breaking number of deals last week, the IPO market cooled off for the shortened holiday week, with just two micro-cap IPOs raising $45 million. Preclinical RNA biotech Transcode Therape